dc.date.accessioned2019-08-28T19:22:42Z
dc.date.accessioned2022-09-23T14:51:01Z
dc.date.available2019-08-28T19:22:42Z
dc.date.available2022-09-23T14:51:01Z
dc.date.created2019-08-28T19:22:42Z
dc.date.issued2015
dc.identifier0975-0851
dc.identifierhttps://www.longdom.org/open-access/bioequivalence-study-of-two-formulations-containing-rosuvastatin-40mg-tablets-in-healthy-colombians-jbb-1000245.pdf
dc.identifierhttp://hdl.handle.net/10818/36914
dc.identifier10.4172/jbb.1000245
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3484283
dc.description.abstractThis is a pharmacokinetic study of two formulations containing Rosuvastatin 40 mg, with the aim to compare the Bioavailability between the Test product (Rosuvastatin made by Laboratorios Tecnoquímicas S.A., Colombia) and the Reference product (Crestor® made by Laboratorios AstraZeneca) in order to declare the Bioequivalence between both formulations. For this, an open-label, two period and two sequences previously randomized, crossover study in 30 healthy volunteers was developed, with a single 40 mg dose in fasting conditions, a washout period of 7 days and 14 plasma samples collection between 0 and 48 hours. For the identification and assessment of plasma Rosuvastatin, an ultra-high performance liquid chromatography coupled to tandem mass spectrometer, UHPLC MS/ MS was the analytical method performed.
dc.languageeng
dc.publisherJournal of J Bioequivalence & Bioavailability
dc.relationJ Bioequiv Availab 2015, 7:5
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rightsopenAccess
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.sourceUniversidad de La Sabana
dc.sourceIntellectum Repositorio Universidad de La Sabana
dc.subjectBioequivalence
dc.subjectRosuvastatin
dc.subjectCholesterol
dc.subjectStatin
dc.subjectPharmacokinetic
dc.titleBioequivalence Study of Two Formulations Containing Rosuvastatin 40 Mg Tablets in Healthy Colombians
dc.typearticle


Este ítem pertenece a la siguiente institución